The pathogenesis of post- infectious irritable bowel syndrome(PI-IBS)involves abnormal intestinal immune barrier, which possibly includes the pathological aspects: Intestinal and systemic changes in T lymphocyte; the change of inflammatory cytokines; a increase in intestinal mast cells and enterochromaffin cells and so on. Treatment by western medicine based largely on symptomatic treatment. TCM thinks that the fundamental organ of the irritable bowel syndrome is the liver. Emotional factors inducing liver dysfunction lead to the symptoms of irritable bowel syndrome. The pathogenesis of IBS is, the disorder of movement of qi in liver and spleen. Stagnation of liver-QI with deficiency of the spleen or disharmony between liver and spleen is the key pathogenesis of post-infectious irritable bowel syndrome. On this basis, in various stages of the disease, there may be a different pathogenesis. As a special type of IBS, the balance of vital qi and evil factors determine the disease progression of PI-IBS, in the treatment course also should not forget dispelling pathogenic factors while strengthening body resistance, tonifying deficiency and removing dampness。

Objective:To build up discriminatory formulas for TCM Syndrome Differentiation Type(TCMSDT) of Aplastic Anemia(AA),discuss ??T subset and their relation with discriminatory formulas.Method:Under the cytometry technique,immuno-indexes in peripheral blood of 34 AA patients and 34 healthy persons were detected.Then build up discriminatory formulas to quantify TCMSDT of AA,and to analyze relations between the subset and TCMSDT.Result:Firstly,absolute value of CD45RA~(+),CD3~(+)CD25~(+) and CD3~(+)HLA-DR~(+),CD3~(+)CD25~(+)(%)and CD4~(+)??T(%)are singled out to make up discriminatory formulas,the total correct ratio is 76.5%.Secondly,vs.control,CD4~(+)??T(%)is statistically in deficiency of kidney-yang group(P

New progress of myelodysplastic syndomes (MDS) in the 55th ASH annual meeting on 5-azacytidine and decitabine was reviewed.Except in older females,the survival time for a diagnosis of MDS in the United States does not seem to have substantially improved since the introduction of 5-azacytidine into the market in 2004.However,clinical and mechanism data suggest that judicious,mechanism-based application and optimization of these agents will have increasingly meaningful impact.Moreover,these drugs are exemplars of an inspiring alternative to the traditional cytotoxic paradigm and should pave the way for additional relatively nontoxic but broadly effective agents.

New progress of myelodysplastic syndomes (MDS) in the 55th ASH annual meeting on allogeneic transplantation were reviewed.Even though the IPSS was developed mainly to determine the prognostic risk in newly diagnosed MDS patients,its predictive value concerning posttransplantation outcome has bcen confirmed in several studies.According to a decision model published a decade ago,patients with intermediate-2 or high-risk MDS by IPSS criteria should be considered for hematopoietic cell transplantation (HCT) at the time of diagnosis if an HLA-matched donor is available at this time.Given the age of most MDS patients,therapeutic interventions are per se often limited to rather nonintensive treatment approaches.This article reviews the current evidence for allogeneic HCT as a therapeutic option in the context of disease-specific characteristics and current available alternative treatments.

Plant alkaloids have anti-tumor activities.In recent years,the anti-tumor mechanisms of plant alkaloid are demonstrated to be related to the block of tumor cell cycle,the induction of tumor cell apoptosis,the inhibition of tumor angiogenesis and multi-drug resistance.In addition,most recently,plant alkaloids are found to inhibit telomerase activity and induce autophagy.Therefore,plant alkaloids may be developed into a sort of potential antitumor drugs.

(-)-Epigallocatechin-3-gallate (EGCG),a natural medicine with anti-neoplastic activity,significantly prevent cancers via inhibiting tumor cell proliferation,suppressing angiogenesis and promoting apoptosis,etc.Furthermore,the new discoveries about anti-tumor mechanisms of EGCG in digestive system,reproductive system and respiratory system shorten the course of EGCG application in clinical.

The research progresses of iron homeostasis and the diagnosis of hereditary iron overload in the 56th American Society of Hematology (ASH) annual meetings were reviewed.Over the last 2 decades,the discovery of mutations in genes leading to hereditary disorders of iron overload,iron deficiency,and iron maldistribution had accelerated our understanding of human iron homeostasis.This article provided an updated overview of the human iron cycle,regulation of iron homeostasis,how perturbations in these homeostatic mechanisms led to iron overload disease and strategies for the diagnosis of hereditary iron overload.

Progress of guidelines for quantifying iron overload in the 56th American Society of Hematology (ASH) annual meetings was reviewed.This article reviewed the use of historical data,serological measures,and MRI to estimate somatic iron burden.Before chelation therapy utilization,transfusional volume was an accurate method for estimating liver iron burden,whereas transferrin saturation reflected the risk of extrahepatic iron deposition.Liver biopsy was invasive and plagued by sampling variability.In the current study,we recommended annual liver iron concentration to be measured by MRI for all patients on chronic transfusion therapy.And it was important to measure cardiac T2* by MRI every 6-24 months depending on the clinical risk of cardiac iron deposition.Recent validation data for pancreas and pituitary iron assessments was also presented,while the further confirmatory data was suggested before these techniques could be recommended for routine clinical use.

New progresses of timing of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndrome (MDS) and aplastic anemia in the 56th ASH annual meetings were reviewed.Allo-HSCT for MDS was a potentially curative procedure,but it was associated with a significant risk of morbidity and mortality.With the recent approval of disease-modifying agents,the appropriate timing of alloHSCT needed to be addressed.For low and intermediate-1 IPSS risk groups,the decision to delay HSCT from the time of diagnosis maximized overall survival.For patients with intermediate-2 and high-risk disease,immediate HSCT at the time of diagnosis was associated with a greater number of life-years than HSCT at a delayed time point.The methods that underwent HSCT were after azacitidine,leukemia-type induction chemotherapy,or both.for severe aplastic anemia (SAA),HSCT was a proven cure,but HLA-matched sibling donors were found in fewer than 25 ％ of newly diagnosed patients.The use of early unrelated donor HSCT was an evolving concept that will became more accepted as improvements in HSCT outcomes continued.Moving forward,HLA-matched related and unrelated donor HSCT will likely become the treatment of choice for most patients with higher-risk MDS and newly diagnosed SAA.

New progress of guidelines for novel targets to iron overload in the 56th American Society of Hematology (ASH) annual meeting was reviewed.β-thalassemia and hereditary hemochromatosis disorders,and inappropriately low levels of the liver hormone hepcidin are responsible for the increased iron absorption,leading to toxic iron accumulation in many organs.Several studies have shown that targeting iron absorption could be beneficial to reducing or preventing iron overload in these 2 disorders.New approaches target Tmprss6.Additional strategies in β-thalassemia are showing beneficial effects in ameliorating ineffective erythropoiesis and anemia.The goal of this review is to discuss the major factors controlling iron metabolism and erythropoiesis and to discuss potential novel therapeutic approaches to reduce or prevent iron overload in these 2 disorders and ameliorate anemia in β-thalassemia.